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Immune myopathies with perimysial pathology (IMPP) have a combination of damage to
perimysial connective tissue and muscle ﬁber necrosis, more prominent near the peri-
mysium. We studied the clinical and laboratory correlates of patients with pathologically
deﬁned IMPP.
Methods
This is a retrospective chart and pathology review of 57 consecutive patients with IMPP
myopathology and, for comparison, 20 patients with dermatomyositis with vascular pathology
(DM-VP).
Results
Compared with DM-VP, IMPP patients more commonly had interstitial lung disease (ILD) (p
< 0.01), Raynaud phenomenon (p < 0.05), mechanic’s hands (p < 0.05), arthralgias (p < 0.001),
and a sustained response to immunomodulatory therapy (p < 0.05), and less frequently had
a concurrent malignancy (p < 0.01). IMPP patients had higher serum creatine kinase values (p <
0.05), more frequent serum Jo-1 (p < 0.03) or SSA/SSA52 autoantibodies (p < 0.05), and less
frequent antinuclear antibodies (p < 0.01). IMPP patients with serum Jo-1/antisynthetase
antibodies were more likely to have ILD (p < 0.05) and inﬂammatory arthritis (p < 0.05) than
IMPP patients without these antibodies.
Conclusions
IMPP myopathology is associated with an increased risk of ILD, Raynaud phenomenon,
mechanic’s hands, and inﬂammatory arthritis when compared with another immune myopathy
(DM-VP). IMPP patients require regular screening for ILD, particularly those with anti-
synthetase antibodies. The absence of myositis-speciﬁc autoantibodies in a large percentage of
IMPP patients emphasizes the important role for myopathology in identifying patients at higher
risk of severe comorbid conditions such as ILD.
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Acquired immune and inﬂammatory myopathies (IIMs) are
a heterogeneous group of disorders. Classiﬁcation schemes
have been based on clinical, autoantibody, or myopathologic
features.1–5 Serum antibodies to aminoacyl-tRNA synthetases
are associated with a multisystem syndrome that includes IIM.
Clinical manifestations include myopathy, interstitial lung
disease (ILD), arthritis, Raynaud phenomenon, and skin rash.
The commonest antisynthetase antibody, anti-Jo-1, is di-
rected against histidyl tRNA synthetase. Myopathology in
patients with anti-Jo-1 antibodies includes damage to peri-
mysial connective tissue and muscle ﬁbers.4,6,7 Perimysial
connective tissue pathology includes damaged structures with
fragmentation and scattered histiocytic cells. Muscle ﬁber
pathology includes necrosis and regeneration, more prom-
inent in regions neighboring the perimysium.We have termed
myopathies with this combined pattern of damage, immune
myopathies with perimysial pathology (IMPP).4 IMPP also
occurs with serum antibodies to hydroxy-methyl-glutaryl-
coenzyme A reductase (HMGCR),8 a nonaminoacyl-tRNA
synthetase antigen. Other patients with IMPP have no asso-
ciated myositis-speciﬁc antibodies (MSA).
This study examined clinical and laboratory features of a co-
hort of consecutive patients with IMPP evaluated at our in-
stitution. We compared IMPP patients with a cohort of
patients with a diﬀerent immune myopathy syndrome, der-
matomyositis with vascular pathology (DM-VP). DM-VP
diﬀers pathologically from IMPP, as it is a myovascular dis-
order. Muscle ﬁber changes are generally atrophy, rather than
the necrosis seen in IMPP.4,9 Our results show that IMPP is
associated with myopathy syndromes having multisystem
features involving muscle, lungs, skin, and joints.
Methods
Patients
We retrospectively reviewed charts, laboratory data, and
muscle biopsies from 57 consecutive patients with muscle
biopsies interpreted as having an IMPP (table 1 and ﬁgure)
who had been clinically evaluated at Washington University
School of Medicine in Saint Louis between 1990 and 2013.
IMPP biopsies had acid phosphatase positive cells in peri-
mysial connective tissue and evidence of myopathy deﬁned as
one of the following: abnormal variation in the muscle ﬁber
size, necrosis or regeneration, or major histocompatibility
complex (MHC) Class I upregulation by muscle ﬁbers. Some
patients in this group were previously reported.6,10 For com-
parison, we reviewed a consecutive series of 20 patients with
biopsies interpreted as DM-VP (Table 1 and ﬁgure). DM-VP
biopsies had vascular pathology, with abnormal endomysial
capillaries or perivascular lymphocytic foci and perifascicular
myopathy with muscle ﬁber atrophy, reduced cytochrome
oxidase staining, or increased MHC Class I expression.
Definition of clinical features
ILD was deﬁned by imaging features, pulmonary function
tests, biopsy data, and/or expert opinion of a pulmonologist.
Inﬂammatory arthritis was deﬁned by imaging features and/or
expert opinion of a rheumatologist. Dermatologic features
were deﬁned by clinical description (i.e., mechanic’s hands,
Gottron sign), biopsy data, and/or expert opinion of a der-
matologist. Myalgias and Raynaud phenomenon were deﬁned
by the clinicians’ documentation as present or absent. Dys-
phagia was deﬁned by objective testing (modiﬁed barium
swallow or endoscopic evaluation of swallowing) and/or ex-
pert opinion of a speech therapist. Paraneoplastic syndromes
were deﬁned as a concurrent cancer diagnosis within a 5-year
period preceding or subsequent to the myopathy diagnosis.
Laboratory data
The initial serum creatine kinase and aldolase values (IU/L)
are reported. Panels of serum MSA were evaluated by clinical
laboratories in Oklahoma or California. HMGCR antibodies
were tested at Washington University in St. Louis.8 Electro-
myographic evidence of an “irritable” myopathy was deﬁned
as the presence of increased insertional or spontaneous ac-
tivity (in the form of ﬁbrillations, positive sharp waves, or
myotonic/repetitive discharges), motor unit potentials of
reduced amplitude and duration, and early recruitment.
Histochemical and
immunohistochemical evaluation
Cryostat sections of rapidly frozen muscle were processed as
previously described.6,11 Immunohistochemical stains were
performed onmuscle cryosections with paired controls on the
same glass slide. Primary antibodies used in this study were
CD4, CD20, C5b-9 complement (membrane attack complex)
(Sigma-Aldrich, St. Louis, MO), and class I humanMHC (US
Biological, Swampscott, MA). Ulex europaeus agglutinin I
lectin (UEA, Sigma-Aldrich) was used to visualize the vascular
endothelium. In most cases, the pathologists interpreting bi-
opsies (A.P. and R.C.B.) were blinded to results of MSA
testing.
Statistical analysis
The Fisher exact test was used to compare categorical varia-
bles. Independent 2-tailed t-tests were used to compare and
Glossary
DM-VP = dermatomyositis with vascular pathology; HMGCR = hydroxy-methyl-glutaryl-coenzyme A reductase; IIM =
immune and inﬂammatory myopathy; ILD = interstitial lung disease; IMPP = immune myopathies with perimysial pathology;
MHC = major histocompatibility complex; MSA = myositis-speciﬁc antibody; RIIM = regional ischemic immune myopathy;
UEA = Ulex europaeus agglutinin.
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report quantitative variables. A p value <0.05 was considered
statistically signiﬁcant between groups. Because this was
a retrospective exploratory study, we did not correct for
multiple comparisons. When clinical or laboratory data were
unavailable, the subject was not included in the analysis for
that feature.
Standard protocol approvals, registrations,
and patient consents
The Human Studies Committee of Washington University in
Saint Louis approved all procedures.
Results
Pathology of IMPP and DM-VP
IMPP patients were chosen based on the presence of peri-
mysial pathology, highlighted by acid phosphatase positive
perimysial cells and alkaline phosphatase staining of the
perimysium, and these features were less common in the
DM-VP group (table 1; ﬁgure). DM-VP patients were chosen
based on the presence of vascular pathology, as deﬁned by any
of the following features, lymphocytic foci surrounding larger
vessels in vascular perimysium, alkaline phosphatase staining
or C5b-9 deposition on endomysial capillaries, or loss of
endomysial capillaries on UEA, and these features were less
common in the IMPP group. Muscle ﬁber necrosis and re-
generation, features not part of the selection process, were
more common in the IMPP group. The most common
pathologic change in muscle ﬁbers in the DM-VP group was
atrophy. Lymphocyte foci containing CD20 B-cells were
more common in DM-VP. CD8 positive T-lymphocytes were
uncommon in both DM-VP and IMPP.
Clinical features of IMPP and DM-VP
Both IMPP (70%) and DM-VP (80%) groups were pre-
dominantly female. Onset ages varied widely in both IMPP
(16–83 years) and DM-VP (7–78 years) groups (table 2).
There were no diﬀerences in age, sex, race, or frequencies of
weakness, dysphagia, and skin rash comparing the IMPP and
Table 1 Myopathology: IMPP and DM-VP groups
IMPP DM-VP
p-Value Odds ratio
Histochemistry % n/57 % n/20
Perimysium
Acid phosphatase+ cells 100 57 20 4 4 × 10213 —
Alkaline phosphatase+ 65 37 20 4 0.0007 7.4
Fragmentation 58 33 20 4 0.004 5.5
Capillaries
Alkaline phosphatase+ 18 10 95 19 7 × 10210 0.011
Muscle fibers
Necrosis/regeneration 88 50 20 4 5 × 1028 28.6
Atrophy, perifascicular 21 12 95 19 0.000004 0.014
COX-fibers, perifascicular 11 6 95 19 6 × 10212 0.006
Immunohistochemistry % n/41 % n/15
Capillaries
Reduced (UEA stain) 20 8 80 12 0.00006 0.061
C5b-9 deposition 29 12 67 10 0.015 0.41
Muscle fibers
MHC-1 expression 85 35 100 15 0.18 0
MHC-1+: perifascicular > other 24 10 60 9 0.024 0.22
Immune cells
CD4+ 85 35 100 15 0.18 0
CD20+ 20 8 80 12 0.00006 0.061
Abbreviations: COX = cytochrome oxidase; DM-VP = dermatomyositis with vascular pathology; IMPP = immunemyopathies with perimysial pathology;MHC =
major histocompatibility complex; UEA = Ulex europaeus agglutinin. Bold values are statistically significant.
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DM-VP groups. Systemic features common in anti-Jo-1 an-
tibody syndromes were all more common in IMPP patients
than DM-VP patients. Features more common in IMPP in-
cluded mechanic’s hands, Raynaud phenomenon, ILD, joint
disorders, and serum antisynthetase antibodies. IMPP
patients were less likely to have an associatedmalignancy or to
die of a malignancy, compared with DM-VP. Causes of death
in the IMPP group were ILD (2), neoplasm (2), and con-
gestive heart failure (1). All deaths (5) in the DM-VP group
were associated with neoplasm. ILD and arthritis were more
common in IMPP patients with antisynthetase antibodies
compared to those without antisynthetase antibodies (ILD =
63% vs 26%, respectively, p = 0.03; arthritis = 94% and 61%,
respectively, p = 0.03). Arthritis was also more common in
antisynthetase antibody-negative IMPP compared with DM-
VP (61% vs 25%, p = 0.03). ILD showed a trend toward
greater frequency in antisynthetase antibody-negative IMPP
compared with DM-VP (26% and 10%, respectively), but the
diﬀerence was not statistically signiﬁcant. Other clinical, lab-
oratory, electrodiagnostic, and myopathologic features were
Figure Comparative myopathology of immune myopathies with perimysial pathology (IMPP) and dermatomyositis with
vascular pathology (DM-VP)
IMPP myopathology includes perimysium that is
widened and damaged (A; H&E stain), occupied by
histiocytic cells (C; acid phosphatase stain), and
stained by alkaline phosphatase (E). Muscle fiber
damage includes necrosis, (membrane attack
complex [C5b-9] deposited in fiber cytoplasm [G]),
more prominent near the perimysium. DM-VP
myopathology includes muscle fiber pathology
with perifascicular atrophy without necrosis (B;
H&E stain) and metabolic changes, including re-
duced staining on cytochrome oxidase (H). DM-VP
vascular pathology includes perivascular (peri-
mysial) lymphocytic inflammation (D; Congo red
stain) and endomysial capillary changes with in-
creased alkaline phosphatase staining (F). Scale
bar = 100 μM (Panels A–H).
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similar in antisynthetase antibody-negative and antibody-
positive IMPP subgroups (data not shown).
Laboratory features of IMPP and DM-VP
Serum creatine kinase and aldolase were 8-fold and 4-fold
higher (p = 0.04) in the IMPP group (table 3), consistent with
the muscle ﬁber necrosis and regeneration that is common in
IMPP but rare in DM-VP (Table 1 and Figure A-H). Jo-1 (p <
0.03) and SSA (p < 0.05) antibodies were more common in
IMPP patients. Forty-six patients in the IMPP cohort and 17
patients in the DM-VP underwent MSA testing. In addition to
Jo-1 and HMGCR, the only other MSA present in the IMPP
cohort were EJ (2) and PL-12 (1), whereas Mi-2 (1) was the
only additionalMSA identiﬁed in theDM-VP cohort. ANAwas
more commonly positive in DM-VP than IMPP patients. C-
reactive protein and erythrocyte sedimentation rate values did
not diﬀer between the 2 groups. Electromyograms showing
“irritable” myopathy were similarly frequent in the 2 groups.
Response to treatment.
The myopathy in all but 1 IMPP patient (98%) had a sus-
tained beneﬁcial response to immunomodulatory therapies,
as measured by strength testing, improvement/resolution of
myalgias, and/or reduction in muscle enzymes. Immuno-
modulatory therapies used in the IMPP group included oral
corticosteroids (n = 47); oral methotrexate (n = 25); pulse
intravenous methylprednisolone (n = 13); azathioprine (n =
12); mycophenolate mofetil (n = 7); rituximab (n = 7); and
intravenous immunoglobulin (n = 4). The myopathy in DM-
VP patients was less responsive to immunomodulatory ther-
apy with only 14 (70%) subjects demonstrating a sustained
beneﬁcial response (p = 0.002). The immunomodulatory
therapies used in the DM-VP cohort were comparable to
those used in the IMPP cohort. Five of the 6 nonresponders in
the DM-VP cohort had paraneoplastic myopathies, suggest-
ing that this factor likely accounted for the diﬀerence in
treatment responsiveness between groups.
Discussion
We have proposed that IIMs are usefully classiﬁed according
to patterns of involvement of diﬀerent tissues in muscle and
types of cellular and humoral immune features.4 In this study,
we compared patients with IMPP, whose distinctive myopa-
thologic features include damage to perimysial connective
Table 2 Clinical features of IMPP and DM-VP
IMPP DM-VP
p-Value Odds ratio% n % n
Epidemiology
Sex: female 70 40/57 80 16/20 0.56
Race: white 75 43/57 65 13/20 0.39
Onset age (y) 47 ± 2 45 ± 5 0.84
Clinical features
Muscle
Weakness 83 45/54 95 19/20 0.27 0.26
Dysphagia 57 29/51 60 12/20 1 0.88
Myalgias 71 37/52 70 14/20 1 1.1
Skin
Rash 76 39/51 75 15/20 1
Mechanic’s hands 33 16/49 5 1/20 0.028 9.2
Raynaud phenomenon 22 11/50 0 0/20 0.027 -
Lung (ILD) 43 23/54 10 2/20 0.011 6.7
Joints (arthritis) 73 38/52 25 5/20 0.0003 8.1
Neoplasm
Frequency 5 3/55 35 7/20 0.003 0.11
Cause of death 4 2/55 25 5/20 0.013 0.11
Abbreviations: DM-VP = dermatomyositis with vascular pathology; ILD = interstitial lung disease; IMPP = immunemyopathies with perimysial pathology. Bold
values are statistically significant.
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tissue, muscle ﬁber necrosis, and histiocytic inﬂammatory
cellularity, to DM-VP, a disorder with large and small vessel
damage, muscle ﬁber atrophy, but not necrosis, and lym-
phocytic perivascular inﬂammation (Table 1; ﬁgure). The
distinctive pathologic features of IMPP and DM-VP in this
study are consistent with previously reported patterns.4,6,7,9,12
Several systemic and laboratory features of patients with
IMPP diﬀered from DM-VP. IMPP patients more often had
joint disorders and ILD. Neoplasm occurrence and cancer-
related deaths were less frequent in IMPP. The type of skin
pathology diﬀered between the groups. Mechanic’s hands and
Raynaud phenomenon were nearly exclusive to IMPP. Serum
Jo-1 antibodies were also more frequent in IMPP (37% vs 6%
in DM-VP).
Clinical syndromes in patients with IMPP myopathology
showed some features that were also common in DM-VP and
immune myopathies in general. These features included fe-
male predominance, wide variability in age at onset, weakness
that is proximal greater than distal and symmetric, dysphagia,
and myalgias. The disease course was subacute or chronic,
with durations over months to years.
The frequency of skin disorders was similar in IMPP and DM-
VP groups. Clinically, approximately 75% of both groups
would have been characterized as dermatomyositis by com-
monly used criteria. Diﬀerences in muscle pathology suggest
that immune dermatomyopathies may actually comprise
several distinct clinical and pathologic syndromes. IMPP
dermatomyopathy syndromes seem likely to be due to con-
nective tissue damage, while DM-VP is probably a vascular
disorder. Another dermatomyopathy syndrome, regional is-
chemic immune myopathy (RIIM), has prominent vascular
pathology with muscle ﬁber necrosis occurring in border-zone
regions of muscle, a diﬀerent pattern from IMPP and DM-
VP.13 Both of these vascular dermatomyopathies (RIIM and
DM-VP) are associated with an increased frequency of neo-
plasms and likely account for a substantial proportion of the
established association between dermatomyositis (as deﬁned
by other criteria) and malignancy.14,15 Overall, it is likely that
the dermatomyopathies, or “dermatomyositis,” should be
considered a group of disorders with varying comorbid con-
ditions beyond skin and muscle, rather than a single
homogeneous disease.
IMPP muscle pathology is associated with a consistent mul-
tisystem disorder, involving muscle, skin, lungs and joints,
which is similar to that associated with serum anti-Jo-1, and,
more generally, antisynthetase, antibodies. However, most of
our patients did not have antisynthetase antibodies, rendering
muscle biopsy considerably more sensitive for deﬁning these
syndromes than serum antibody testing.
Although antisynthetase antibodies commonly occur in
a subset of IMPP, the relationship of these antibodies directed
against intracellular antigens to disease pathogenesis remains
unclear. The pattern of muscle pathology suggests that the
antigenic targets in IMPP are likely related to connective
tissue, which could explain the pattern of multisystem in-
volvement. Acid phosphatase–positive perimysial histiocytes
in IMPP are a notable myopathologic diﬀerence from the
perivascular lymphocytes present in DM-VP. It is possible
that these acid phosphatase positive histiocytes, a signature
Table 3 Laboratory and electrodiagnostic features: IMPP vs DM-VP
IMPP DM-VP p-Value
Disease activity marker
Creatine kinase (U/L) 3,543 ± 760 457 ± 670 0.04
Aldolase (U/L) 45 ± 18 10 ± 4 0.04
Sedimentation rate (mm/h) 33 ± 5 26 ± 8 0.47
C-reactive protein (mg/L) 14 ± 7 5 ± 2 0.07
Antibody marker % n % n p-Value Odds ratio
ANA ≥1:160 51 23/45 89 16/18 0.009 0.13
Jo-1* 37 17/46 6 1/17 0.025 9.4
SSA/SSA52 23 9/40 0 0/18 0.045 —
HMGCR 40 8/20 14 1/7 0.4 4.0
Electromyography: irritable myopathy 77 30/39 82 14/17 0.74 0.71
Abbreviations: ANA =antinuclear antibody; DM-VP =dermatomyositis with vascular pathology; HMGCR-3 =hydroxy-3-methyl-glutaryl-coenzymeA reductase;
IMPP = immune myopathies with perimysial pathology. Bold values are statistically significant.
* Additional myositis-specific antibody (MSA) identified in the IMPP group included EJ (2) and PL-12 (1), while Mi-2 (1) was the only other MSA identified in the
DM-VP group.
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feature of IMPP, are ultimately responsible for the muscle
ﬁber necrosis typical of this condition, perhaps via cytokine-
mediated pathways diﬀerent from those associated with
muscle ﬁber atrophy and regeneration in other forms of im-
mune myopathy.16 It is well established in hereditary dis-
orders that abnormalities in connective tissue proteins can
produce severe myopathies.17–20 Further search for the spe-
ciﬁc tissue autoantigens (possibly in connective tissue), and
how perimysial pathology leads to muscle ﬁber necrosis, in
IMPP will be important.
Our results are the outcome of a retrospective study of muscles
from patients, most of whom presented to neurologists with
primary complaints of weakness. Prospective studies would be
useful to test our ﬁndings that IMPP is associated with dis-
tinctive multisystem disorders in adults and children. Studies of
the frequency and types of IMPP myopathy and lung and skin
pathology in patients presenting with ILD or skin disorders
could provide further information about systemic immune
disorders aﬀecting connective tissue. Larger series could also
evaluate whether antisynthetase and other serum autoanti-
bodies in IMPP patients such as anti-HMGCR are associated
with speciﬁc subgroups of pathologic changes and clinical
system involvement. A limitation of our study, given its retro-
spective nature, is that we could not guarantee that diagnostic
testing, including MSA testing, was uniform across all subjects.
While over 80% of the subjects in both cohorts did undergo
some form of MSA testing, this study includes subjects evalu-
ated over a 24-year period that coincided with a substantial
increase in the number of myositis-speciﬁc autoantibodies
available for clinical testing. Future prospective studies, ideally
with serum banking to allow for retrospective testing of newly
identiﬁed autoantibodies, are ultimately necessary to determine
the actual prevalence of MSA in these disorders.
In any case, IMPP syndromes appear to be a distinctive
subgroup of disorders that do not ﬁt well into the current
classiﬁcations of immune myopathies as polymyositis and
dermatomyositis. The absence of myositis-speciﬁc autoanti-
bodies in a large percentage of IMPP patients emphasizes an
important role for myopathology in identifying these patients
at an increased risk of ILD and distinguishing them from IIM
patients with an increased risk of malignancy.
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